Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study

Genetic Mechanisms in Human Hypertension RAAS Inhibition Study

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01009944

Enrollment

Registered

2009-11-09

Start date

2007-01-31

Completion date

2019-03-19

Last updated

2021-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

High blood pressure

Brief summary

The purpose of this study is to develop an approach to provide personalized medicine to individuals who have hypertension (high blood pressure). The investigators plan to use people's genetic characteristics (traits) to determine what medication they should use to lower their blood pressure most effectively. The investigators will give individuals one of two medications to treat hypertension (lisinopril or atenolol). The investigators believe that depending on the individuals genetic background one medication will work better in lowering their blood pressure.

Interventions

DRUGLisinopril, Atenolol

once a day for 14 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Male and female hypertensive participants who were previously studied in SCOR program.

Exclusion criteria

* Diabetes * Taking other medications beside thyroid or estrogen supplements.

Design outcomes

Primary

Measure	Time frame
One type of blood pressure medication will better treat individuals with certain genetic backgrounds.	16 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026